CBAY
$8.36
Cymabay Therapeutics
($.10)
(1.18%)
CBAY
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  ($0.17)
Revenue:  $0.00 Mil
Monday
Nov 9
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CBAY reports earnings?
Beat
Meet
Miss

Where is CBAY's stock price going from here?
Up
Flat
Down
Stock chart of CBAY
Analysts
Summary of analysts' recommendations for CBAY
Score
Grade
Pivots
Resistance
$8.95
$8.77
$8.57

$8.39

Support
$8.19
$8.01
$7.81
Tweet
Growth
Description
CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California.
Peers
InterCeptRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalZoetisBristol-Myers SquibbJohnson & JohnsonMerck & Co.PfizerUltragenyx Pharmaceutical